Oncomed Pharmaceuticals Inc Quick Ratio (OMED) starting from the fourth quarter 2018 to fourth quarter 2017, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Oncomed Pharmaceuticals Inc  (OMED)

Oncomed Pharmaceuticals Inc's Quick Ratio

OMED's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Oncomed Pharmaceuticals Inc's Cash & cash equivalent, this led to improvement in Oncomed Pharmaceuticals Inc's Quick Ratio to 4.54, above Oncomed Pharmaceuticals Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 212 other companies have achieved higher Quick Ratio than Oncomed Pharmaceuticals Inc in fourth quarter 2018. While Quick Ratio total ranking has improved so far during the Q4 2018 to 686, from total ranking in the third quarter 2018 at 698.

Explain Quick Ratio?
How much Cash & cash equivalents OMED´s has?
What are OMED´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OMED Quick Ratio (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3		 (Jun 30 2018)
Q2		 (Mar 31 2018)
Q1		 (Dec 31 2017)
Q4
Y / Y Current Liabilities Change -85.74 % -16.21 % 21.69 % 2.66 % 83.8 %
Y / Y Cash & cash equivalent Change -44.37 % -37.62 % -38.45 % -43.66 % -44.15 %
Quick Ratio MRQ 4.54 3.32 2.4 2.8 1.16
OMED's Total Ranking # 686 # 698 # 688 # 968 # 986
Seq. Current Liabilities Change -40.75 % -35.78 % 5.22 % -64.4 % 248.3 %
Seq. Cash & cash equivalent Change -19.07 % -11.28 % -9.68 % -14.23 % -9.24 %



Quick Ratio fourth quarter 2018 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 213
Healthcare Sector # 326
Overall Market # 686


Quick Ratio Statistics
High Average Low
6.18 4.34 1.16
(Mar 31 2015)   (Dec 31 2017)




Financial Statements
Oncomed Pharmaceuticals Inc's Current Liabilities $ 13 Millions Visit OMED's Balance sheet
Oncomed Pharmaceuticals Inc's Cash & cash equivalent $ 57 Millions Visit OMED's Balance sheet
Source of OMED's Sales Visit OMED's Sales by Geography


Cumulative Oncomed Pharmaceuticals Inc's Quick Ratio

OMED's Quick Ratio for the trailling 12 Months

OMED Quick Ratio

 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months		 (Jun 30 2018)
12 Months		 (Mar 31 2018)
12 Months		 (Dec 31 2017)
12 Months
Y / Y Current Liabilities TTM Growth -42.64 % 32.67 % 10.61 % 1.77 % -8.25 %
Y / Y Cash & cash equivalent TTM Growth -41.1 % -41.48 % -43.29 % -39.65 % -33.52 %
Quick Ratio TTM 3 1.96 2.15 2.51 2.92
Total Ranking TTM # 4741 # 4828 # 4813 # 4794 # 612
Seq. Current Liabilities TTM Growth -43.5 % -2.31 % 3.42 % 0.47 % 30.68 %
Seq. Cash & cash equivalent TTM Growth -13.37 % -11.1 % -11.48 % -13.61 % -13.93 %

Quick ratio ranking by company, industry and sector >> Back to OMED Financial Strength Comparisons >> Go to Compare OMED Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Oncomed Pharmaceuticals Inc's average Cash & cash equivalent, this led to increase in in Oncomed Pharmaceuticals Inc's Quick Ratio to 3, Quick Ratio remained below OMED average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Oncomed Pharmaceuticals Inc. While Quick Ratio overall ranking has improved so far to 4741, from total ranking during the twelve months ending third quarter 2018 at 4828.

Explain Quick Ratio?
How much Cash & cash equivalents OMED´s has?
What are OMED´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 432
Healthcare Sector # 830
Within the Market # 4741


trailing twelve months Quick Ratio Statistics
High Average Low
5.91 3.93 1.87
(Jun 30 2015)   (Sep 30 2018)




Companies with similar Quick Ratio in the quarter ending Dec 31 2018, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2018 MRQ Cash & cash equivalentDec 31 2018 MRQ Current Liabilities
Taiwan Liposome Company Ltd   12.39 $ 27.001  Millions$ 2.180  Millions
Notable Labs Ltd   12.29 $ 58.694  Millions$ 4.774  Millions
Quantum Biopharma Ltd   12.12 $ 15.900  Millions$ 1.312  Millions
Ac Immune Sa  11.96 $ 159.135  Millions$ 13.306  Millions
Vanda Pharmaceuticals Inc   11.92 $ 257.360  Millions$ 21.584  Millions
Korro Bio Inc   11.68 $ 42.189  Millions$ 3.612  Millions
Rapt Therapeutics Inc   11.52 $ 63.798  Millions$ 5.540  Millions
Karuna Therapeutics Inc   11.51 $ 13.887  Millions$ 1.207  Millions
Whitehawk Therapeutics Inc   11.47 $ 62.614  Millions$ 5.457  Millions
Abeona Therapeutics Inc   11.45 $ 84.968  Millions$ 7.418  Millions
Dicerna Pharmaceuticals Inc   11.29 $ 302.626  Millions$ 26.793  Millions
F star Therapeutics Inc   11.22 $ 47.638  Millions$ 4.247  Millions
Alnylam Pharmaceuticals Inc   11.18 $ 1,967.033  Millions$ 175.998  Millions
Zymeworks Inc   11.09 $ 200.164  Millions$ 18.055  Millions
Xeris Biopharma Holdings Inc   11.07 $ 112.633  Millions$ 10.172  Millions
Immune Design Corp.  10.84 $ 95.887  Millions$ 8.845  Millions
Corcept Therapeutics Inc  10.84 $ 398.970  Millions$ 36.808  Millions
Sage Therapeutics Inc   10.73 $ 922.776  Millions$ 86.030  Millions
Marinus Pharmaceuticals Inc   10.53 $ 72.725  Millions$ 6.909  Millions
Proqr Therapeutics N v   10.49 $ 118.250  Millions$ 11.274  Millions
Apellis Pharmaceuticals Inc   10.35 $ 176.268  Millions$ 17.025  Millions
Kala Bio inc   10.33 $ 170.898  Millions$ 16.547  Millions
Unity Biotechnology Inc   10.32 $ 171.135  Millions$ 16.582  Millions
Arbutus Biopharma Corp  10.29 $ 124.617  Millions$ 12.110  Millions
Iterum Therapeutics Plc  9.91 $ 124.273  Millions$ 12.534  Millions
Kura Oncology Inc   9.88 $ 178.985  Millions$ 18.115  Millions
Five Prime Therapeutics Inc   9.83 $ 270.138  Millions$ 27.487  Millions
Decoy Therapeutics Inc   9.79 $ 3.355  Millions$ 0.343  Millions
Turning Point Therapeutics Inc.  9.73 $ 101.102  Millions$ 10.395  Millions
Intra cellular Therapies Inc   9.57 $ 347.531  Millions$ 36.299  Millions

Date modified: 2026-09-26T08:31:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.